Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

Vimalanand S. Prabhu; Oliver A. Cornely; Yoav Golan; Erik R. Dubberke; Sebastian M. Heimann; Mary E. Hanson; Jane Liao; Alison Pedley; Mary Beth Dorr; Stephen Marcella

doi:10.1093/cid/cix523

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

Vimalanand S. Prabhu, Oliver A. Cornely, Yoav Golan, Erik R. Dubberke, Sebastian M. Heimann, Mary E. Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, Stephen Marcella

Research output: Contribution to journal › Article

9 Scopus citations

Abstract

We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

Original language	English
Pages (from-to)	1218-1221
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	65
Issue number	7
DOIs	https://doi.org/10.1093/cid/cix523
State	Published - Oct 1 2017

Keywords

C. difficile infection
bezlotoxumab
hospital readmissions
recurrence

Access to Document

10.1093/cid/cix523

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection'. Together they form a unique fingerprint.

Cite this

Prabhu, V. S., Cornely, O. A., Golan, Y., Dubberke, E. R., Heimann, S. M., Hanson, M. E., Liao, J., Pedley, A., Dorr, M. B., & Marcella, S. (2017). Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection. Clinical Infectious Diseases, 65(7), 1218-1221. https://doi.org/10.1093/cid/cix523

Prabhu, Vimalanand S. ; Cornely, Oliver A. ; Golan, Yoav ; Dubberke, Erik R. ; Heimann, Sebastian M. ; Hanson, Mary E. ; Liao, Jane ; Pedley, Alison ; Dorr, Mary Beth ; Marcella, Stephen. / Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection. In: Clinical Infectious Diseases. 2017 ; Vol. 65, No. 7. pp. 1218-1221.

@article{e7732d06fd0445d9b04e6630d268bc2f,

title = "Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection",

abstract = "We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).",

keywords = "C. difficile infection, bezlotoxumab, hospital readmissions, recurrence",

author = "Prabhu, {Vimalanand S.} and Cornely, {Oliver A.} and Yoav Golan and Dubberke, {Erik R.} and Heimann, {Sebastian M.} and Hanson, {Mary E.} and Jane Liao and Alison Pedley and Dorr, {Mary Beth} and Stephen Marcella",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/cid/cix523",

language = "English",

volume = "65",

pages = "1218--1221",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

number = "7",

}

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection. / Prabhu, Vimalanand S.; Cornely, Oliver A.; Golan, Yoav; Dubberke, Erik R.; Heimann, Sebastian M.; Hanson, Mary E.; Liao, Jane; Pedley, Alison; Dorr, Mary Beth; Marcella, Stephen.

In: Clinical Infectious Diseases, Vol. 65, No. 7, 01.10.2017, p. 1218-1221.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection

AU - Prabhu, Vimalanand S.

AU - Cornely, Oliver A.

AU - Golan, Yoav

AU - Dubberke, Erik R.

AU - Heimann, Sebastian M.

AU - Hanson, Mary E.

AU - Liao, Jane

AU - Pedley, Alison

AU - Dorr, Mary Beth

AU - Marcella, Stephen

PY - 2017/10/1

Y1 - 2017/10/1

N2 - We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

AB - We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).

KW - C. difficile infection

KW - bezlotoxumab

KW - hospital readmissions

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85030669720&partnerID=8YFLogxK

U2 - 10.1093/cid/cix523

DO - 10.1093/cid/cix523

M3 - Article

C2 - 30060024

AN - SCOPUS:85030669720

VL - 65

SP - 1218

EP - 1221

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -